DNA sequencing is an indispensable method in fundamental research of normal and cancer biology. Next-generation sequencing has revolutionized biological science by reducing cost, improving turnaround time and reducing sample input requirements compared to regular qPCR and the Sanger method. Dr. Noon, a dedicated expert in bladder cancer, summarized the most contemporary evidence on next-generation sequencing in NMIBC.
Due to the aggressive nature of Muscle-invasive and advanced urothelial cancer, multimodal therapy including radical cystectomy with neoadjuvant or adjuvant systemic chemotherapy represents a standard of care in urothelial carcinoma treatment. Several important findings on systemic perioperative therapies were published in the past years. Dr. Seisen, a brilliant researcher, presents an overview of the best evidence and the state-of-the-art in perioperative chemotherapy in 2017.
One of the key challenges in improving outcomes for UCB is the heterogeneity of the disease. In the last few years a couple of landmark studies were published investigating the complicated, variable molecular pattern of UCB (9, 10) . Especially MIBC presents large genetic and molecular variability. Dr. Seiler, a young world-wide recognized expert in molecular UCB biology, summarizes the current knowledge and implications of genetically complexity of MIBC that need to be addressed in drug development.
Despite there is evidence that neoadjuvant and adjuvant Cisplatin-based chemotherapy may improve survival in UCB, only a limited number of patients receive these treatments. The reasons for this are obviously multifarious, but the mixed response and underlying biology are an essential clinical issue. Dr. Roghmann, an accomplished clinician-researcher, is answering the question if we have biomarkers to predict response to neoadjuvant or adjuvant chemotherapy.
In addition to this, Prof. Dr. Shariat, a world-leading authority in clinical and translational bladder cancer research, is comprehensively presenting the latest evidence on genetic determinants for chemo-and radiotherapy resistance in bladder cancer.
While urine may frequently contain epitopes and genetic material from UCB, genomic characteristics may vary between the primary tumor site and distant sites (13) . Blood represents another source for liquid biopsies. Tumor cells in the peripheral circulation may not only represent an indicator for metastatic spread, but also may be used for genetic analyses investigating differences between the primary tumor site and metastases, which may be a reason for treatment failure. Dr. Riethdorf, a foremost expert in the field of circulating tumor cells, presents the state-of-art of circulating tumor cells and circulating cellfree tumor DNA in bladder cancer.
In these days, one of the most exciting findings was the response of UCB to immuno-oncologic therapies. In recent years, a large number of industry-sponsored trials were published and the introduction of PD-1/PD-L1 checkpoint inhibition changed our current treatment strategies in UCB. Dr Necchi and Dr. von Rundstedt, two brilliant medical and surgical scientists, summarize and discuss the evidence on UCB biomarker in the era of immuno-oncology.
Last but not least, the role of consolidative extirpative surgery in metastatic UCB is still unproven. In patients with clinically evident lymph node metastasis, data suggest a survival advantage for patients undergoing postchemotherapy radical cystectomy with lymphadenectomy (14) . The benefit of metastasis surgery in distant metastatic UCB is unclear. Dr. Decaestecker, a great surgeon scientist, presents a perspective on this controversial topic.
Finally, Dr. Gild and Dr. Meyer, two rising stars, present a comprehensive workup of online tools for patient counseling. According to the increasing number of prognostic tools in cancer care, and the broad presence and use of the Internet in daily clinical practice, their review presents an elegant overview about the availability and accessibility of online tools.
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